Grace Therapeutics
GRCE
12 hedge funds and large institutions have $205K invested in Grace Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.08% → 0.06% (-0.01%)
20% less capital invested
Capital invested by funds: $255K → $205K (-$50.1K)
20% less funds holding
Funds holding: 15 → 12 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$42.7K |
| 2 |
Morgan Stanley
New York
|
+$25.1K |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$14.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.41K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$88K |
| 2 |
Jane Street
New York
|
-$23K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$19K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of America
Charlotte,
North Carolina
| $69K | +$42.7K | +5,994 | +174% |
|
|
2
Morgan Stanley
New York
| $66K | +$25.1K | +3,522 | +63% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $22K | – | – | – |
|
|
4
National Bank of Canada
Montreal,
Quebec, Canada
| $22K | +$1.15K | +161 | +6% |
|
|
EDRH
5
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $15K | +$14.9K | +2,083 | New |
|
|
SIAP
6
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
| $6K | – | – | – |
|
7
Koshinski Asset Management
Decatur,
Illinois
| $2.44K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1K | +$321 | +45 | +79% |
|
|
9
UBS Group
Zurich,
Switzerland
| $1K | +$1.41K | +198 | New |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $276 | – | – | – |
|
|
11
Renaissance Technologies
New York
| – | -$88K | -11,630 | Closed |
|
|
12
Jane Street
New York
| – | -$23K | -3,067 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$19K | -2,453 | Closed |
|
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2.23K | -313 | -89% |
|
GRCE Hedge Fund Activity: Q1 2022 in Review
12 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2022, worth a combined $205K — down 20% from $255K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GRCE and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Bank of America, adding an estimated $42.7K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $88K sold.
- 12 institutional investors held Grace Therapeutics (GRCE) as of Q1 2022, down from 15 in Q4 2021.
- Funds reported $205K of Grace Therapeutics stock for Q1 2022, down 20% quarter-over-quarter.
- 2 funds opened new Grace Therapeutics positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Grace Therapeutics buyer in Q1 2022 was Bank of America, an estimated $42.7K added.
- The largest Grace Therapeutics seller in Q1 2022 was Renaissance Technologies, an estimated $88K sold.
Based on aggregated 13F filings for Q1 2022.